Takayuki Ikezoe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6156008/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Molecular Cancer Therapeutics, 2007, 6, 1851-1857.	4.1	122
2	Thrombomodulin/activated protein C system in septic disseminated intravascular coagulation. Journal of Intensive Care, 2015, 3, 1.	2.9	102
3	The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Molecular Cancer Therapeutics, 2006, 5, 2522-2530.	4.1	100
4	Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leukemia Research, 2007, 31, 673-682.	0.8	95
5	Inhibition of IRE1α-driven pro-survival pathways is a promising therapeutic application in acute myeloid leukemia. Oncotarget, 2016, 7, 18736-18749.	1.8	71
6	Insulin-like growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cells. Blood, 2004, 104, 237-242.	1.4	69
7	Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematology,the, 2020, 7, e218-e225.	4.6	65
8	Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin. International Journal of Hematology, 2014, 100, 27-37.	1.6	64
9	Thrombomodulin Protects Endothelial Cells From a Calcineurin Inhibitor–Induced Cytotoxicity by Upregulation of Extracellular Signal–Regulated Kinase/Myeloid Leukemia Cell-1 Signaling. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2259-2270.	2.4	54
10	Downregulation of miRâ€217 correlates with resistance of ph ⁺ leukemia cells to <scp>ABL</scp> tyrosine kinase inhibitors. Cancer Science, 2014, 105, 297-307.	3.9	54
11	Effect of SU11248 on gastrointestinal stromal tumor-T1 cells: Enhancement of growth inhibition via inhibition of 3-kinase/Akt/mammalian target of rapamycin signaling. Cancer Science, 2006, 97, 945-951.	3.9	52
12	CCAAT/Enhancer-Binding Protein δ: A Molecular Target of 1,25-Dihydroxyvitamin D3 in Androgen-Responsive Prostate Cancer LNCaP Cells. Cancer Research, 2005, 65, 4762-4768.	0.9	51
13	Recombinant human soluble thrombomodulin safely and effectively rescues acute promyelocytic leukemia patients from disseminated intravascular coagulation. Leukemia Research, 2012, 36, 1398-1402.	0.8	41
14	Expression of pâ€JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia. International Journal of Cancer, 2011, 129, 2512-2521.	5.1	40
15	PC-SPES: A Potent Inhibitor of Nuclear Factor-κB Rescues Mice from Lipopolysaccharide-Induced Septic Shock. Molecular Pharmacology, 2003, 64, 1521-1529.	2.3	39
16	CD34 ⁺ /CD38 ^{â^'} acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells. International Journal of Cancer, 2013, 132, 2006-2019.	5.1	38
17	Mitochondrial STAT3 exacerbates LPS-induced sepsis by driving CPT1a-mediated fatty acid oxidation. Theranostics, 2022, 12, 976-998.	10.0	37
18	Analysis of Aurora B kinase in non-Hodgkin lymphoma. Laboratory Investigation, 2009, 89, 1364-1373.	3.7	36

#	Article	IF	CITATIONS
19	Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematology,the, 2021, 8, e902-e911.	4.6	30
20	A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year results. Genetics in Medicine, 2022, 24, 1425-1436.	2.4	30
21	CD82 regulates STAT5/ILâ€10 and supports survival of acute myelogenous leukemia cells. International Journal of Cancer, 2014, 134, 55-64.	5.1	29
22	p53 is critical for the Aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells. International Journal of Hematology, 2010, 91, 69-77.	1.6	28
23	Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6. Journal of Biological Chemistry, 2017, 292, 4280-4292.	3.4	27
24	The BCR/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1β in vascular endothelium in association with downregulation of miR-3p. Leukemia Research, 2017, 58, 83-90.	0.8	26
25	HIV-1 Protease Inhibitor Ritonavir Potentiates the Effect of 1,25-Dihydroxyvitamin D3 to Induce Growth Arrest and Differentiation of Human Myeloid Leukemia Cells Via Inhibition of CYP24 Blood, 2004, 104, 2543-2543.	1.4	25
26	HIV-1 protease inhibitor ritonavir potentiates the effect of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of human myeloid leukemia cells via down-regulation of CYP24. Leukemia Research, 2006, 30, 1005-1011.	0.8	24
27	The Fifth Epidermal Growth Factor–like Region of Thrombomodulin Alleviates Murine Graft-versus-Host Disease in a G-Protein Coupled Receptor 15 Dependent Manner. Biology of Blood and Marrow Transplantation, 2017, 23, 746-756.	2.0	24
28	Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies. International Journal of Hematology, 2021, 113, 34-44.	1.6	24
29	Inhibition of signal transducer and activator of transcription 5 by the inhibitor of janus kinases stimulates dormant human leukemia CD34+/CD38â^'cells and sensitizes them to antileukemia agents. International Journal of Cancer, 2011, 128, 2317-2325.	5.1	21
30	G-protein coupled receptor 15 mediates angiogenesis and cytoprotective function of thrombomodulin. Scientific Reports, 2017, 7, 692.	3.3	21
31	Thrombomodulin enhances the antifibrinolytic and antileukemic effects of all–trans retinoic acid in acute promyelocytic leukemia cells. Experimental Hematology, 2012, 40, 457-465.	0.4	20
32	BCR/ABL increases EZH2 levels which regulates XIAP expression via miRNA-219 in chronic myeloid leukemia cells. Leukemia Research, 2016, 45, 24-32.	0.8	20
33	The fifth epidermal growth factor like region of thrombomodulin alleviates LPS-induced sepsis through interacting with GPR15. Thrombosis and Haemostasis, 2017, 117, 570-579.	3.4	20
34	Micro <scp>RNA</scp> â€9 plays a role in interleukinâ€10â€mediated expression of Eâ€cadherin in acute myelogenous leukemia cells. Cancer Science, 2017, 108, 685-695.	3.9	19
35	Effects of eculizumab treatment on quality of life in patients with paroxysmal nocturnal hemoglobinuria in Japan. International Journal of Hematology, 2018, 107, 656-665.	1.6	19
36	miR-217 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitors by targeting pro-oncogenic anterior gradient 2. Experimental Hematology, 2018, 68, 80-88.e2.	0.4	18

#	Article	IF	CITATIONS
37	Clinical effects of recombinant thrombomodulin and defibrotide on sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 674-680.	2.4	18
38	Assessment of dysplasia in bone marrow smear with convolutional neural network. Scientific Reports, 2020, 10, 14734.	3.3	18
39	Effect of recombinant human soluble thrombomodulin on clinical outcomes of patients with coagulopathy after hematopoietic stem cell transplantation. European Journal of Haematology, 2013, 91, 442-447.	2.2	16
40	Tetraspanin Family Member, CD82, Regulates Expression of EZH2 via Inactivation of p38 MAPK Signaling in Leukemia Cells. PLoS ONE, 2015, 10, e0125017.	2.5	16
41	Recombinant Human Soluble Thrombomodulin Enhances the Anti-Fibrinolytic and Anti-Leukemia Effects of All-Trans Retinoic Acid In Acute Promyelocytic Leukemia Cells Blood, 2010, 116, 1079-1079.	1.4	16
42	Possibility of cancer-stem-cell-targeted radioimmunotherapy for acute myelogenous leukemia using 211At-CXCR4 monoclonal antibody. Scientific Reports, 2020, 10, 6810.	3.3	14
43	Defibrotide Stimulates Angiogenesis and Protects Endothelial Cells from Calcineurin Inhibitor-Induced Apoptosis via Upregulation of AKT/Bcl-xL. Thrombosis and Haemostasis, 2018, 118, 161-173.	3.4	13
44	A critical role of the Gas6-Mer axis in endothelial dysfunction contributing to TA-TMA associated with GVHD. Blood Advances, 2019, 3, 2128-2143.	5.2	13
45	Inhibition of Aurora-A Promotes CD8+ T-Cell Infiltration by Mediating IL10 Production in Cancer Cells. Molecular Cancer Research, 2020, 18, 1589-1602.	3.4	13
46	Analysis of the association between resolution of disseminated intravascular coagulation (DIC) and treatment outcomes in post-marketing surveillance of thrombomodulin alpha for DIC with infectious disease and with hematological malignancy by organ failure. Thrombosis Journal, 2020, 18, 2.	2.1	13
47	Diffuse alveolar hemorrhage associated with lenalidomide. International Journal of Hematology, 2011, 93, 830-831.	1.6	12
48	STAT5A regulates DNMT3A in CD34+/CD38â^ AML cells. Leukemia Research, 2015, 39, 897-905.	0.8	12
49	Cytoprotective and pro-angiogenic functions of thrombomodulin are preserved in the C loop of the fifth epidermal growth factor-like domain. Haematologica, 2018, 103, 1730-1740.	3.5	12
50	The suppressive effects of Mer inhibition on inflammatory responses in the pathogenesis of LPS-induced ALI/ARDS. Science Signaling, 2022, 15, eabd2533.	3.6	12
51	Targeting HLA-F suppresses the proliferation of glioma cells via a reduction in hexokinase 2-dependent glycolysis. International Journal of Biological Sciences, 2021, 17, 1263-1276.	6.4	11
52	Over-expression of Mcl-1 impairs the ability of ATRA to induce growth arrest and differentiation in acute promyelocytic leukemia cells. Apoptosis: an International Journal on Programmed Cell Death, 2013, 18, 1403-1415.	4.9	10
53	Disseminated intravascular coagulation in non-Hodgkin lymphoma. International Journal of Hematology, 2015, 102, 413-419.	1.6	10
54	Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantation. Journal of Blood Medicine, 2016, 7, 1.	1.7	10

#	Article	IF	CITATIONS
55	Circulating intranuclear proteins may play a role in development of disseminated intravascular coagulation in individuals with acute leukemia. International Journal of Hematology, 2020, 111, 378-387.	1.6	9
56	Blockade of CD 82 by a monoclonal antibody potentiates antiâ€leukemia effects of AraC inÂvivo. Cancer Medicine, 2015, 4, 1426-1431.	2.8	8
57	Hypofibrinogenemia is associated with a high degree of risk in infectious diseases: a post-hoc analysis of post-marketing surveillance of patients with disseminated intravascular coagulation treated with thrombomodulin alfa. Thrombosis Journal, 2021, 19, 12.	2.1	8
58	C/EBPδ Modulates Cell Growth, Differentiation and Apoptosis of Myeloid Leukemia, Prostate and Breast Cancer Cells Blood, 2004, 104, 4300-4300.	1.4	8
59	Optimal timing of apheresis for the efficient mobilization of peripheral blood progenitor cells recruited by high-dose granulocyte colony-stimulating factor in healthy donors. Transfusion and Apheresis Science, 2020, 59, 102737.	1.0	7
60	Diagnosis and treatment of disseminated intravascular coagulation in COVID-19 patients: a scoping review. International Journal of Hematology, 2021, 113, 320-329.	1.6	7
61	JAK2V617F Mutation Promoted IL-6 Production and Glycolysis via Mediating PKM1 Stabilization in Macrophages. Frontiers in Immunology, 2020, 11, 589048.	4.8	6
62	<i>Aurka</i> deficiency in the intestinal epithelium promotes age-induced obesity via propionate-mediated AKT activation. International Journal of Biological Sciences, 2021, 17, 1302-1314.	6.4	6
63	PC-SPES down-regulates COX-2 via inhibition of NF-kappaB and C/EBPbeta in non-small cell lung cancer cells. International Journal of Oncology, 2006, 29, 453-61.	3.3	6
64	Results from multinational phase 3 studies of ravulizumab (ALXN1210) versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria: subgroup analysis of Japanese patients. International Journal of Hematology, 2020, 112, 466-476.	1.6	5
65	Heterogeneity in the diagnosis of plasmablastic lymphoma, plasmablastic myeloma, and plasmablastic neoplasm: a scoping review. International Journal of Hematology, 2021, 114, 639-652.	1.6	5
66	A possible role of low regulatory T cells in anti-acetylcholine receptor antibody positive myasthenia gravis after bone marrow transplantation. BMC Neurology, 2017, 17, 93.	1.8	4
67	In vitro studies on the role of recombinant human soluble thrombomodulin in the context of retinoic acid mediated APL differentiation syndrome. Leukemia Research, 2017, 63, 1-9.	0.8	4
68	Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease. Internal Medicine, 2018, 57, 3651-3657.	0.7	4
69	Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice. Journal of Hematology and Oncology, 2021, 14, 52.	17.0	4
70	An evaluation of the Japanese Society on Thrombosis and Hemostasis criteria for disseminated intravascular coagulation as a predictor of prognosis in patients with infection. International Journal of Laboratory Hematology, 2021, 43, 1566-1574.	1.3	4
71	Dasatinib induces endothelial-to-mesenchymal transition in human vascular-endothelial cells: counteracted by cotreatment with bosutinib. International Journal of Hematology, 2021, 113, 441-455.	1.6	4
72	Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan. International Journal of Hematology, 2022, 115, 470-480.	1.6	4

#	Article	IF	CITATIONS
73	Steroid-resistant autoimmune myelofibrosis in a patient with autoimmune hepatitis and Evans syndrome complicated with increased expression of TGF- ¹² in the bone marrow: a case report. International Journal of Hematology, 2017, 106, 718-724.	1.6	3
74	The link between interleukin-1β and acute myocardial infarction in chronic myeloid leukemia patients treated with nilotinib: cross-sectional study. Annals of Hematology, 2020, 99, 359-361.	1.8	3
75	Treatment of T-Cell Prolymphocytic Leukemia with Central Nervous System Involvement Using Intrathecal Alemtuzumab Administration. Case Reports in Hematology, 2020, 2020, 1-4.	0.4	3
76	<i>Aurka</i> loss in CD19 ⁺ B cells promotes megakaryocytopoiesis via IL-6/STAT3 signaling-mediated thrombopoietin production. Theranostics, 2021, 11, 4655-4671.	10.0	3
77	Simultaneous silencing Aurora-A and UHRF1 inhibits colorectal cancer cell growth through regulating expression of DNMT1 and STAT1. International Journal of Medical Sciences, 2021, 18, 3437-3451.	2.5	3
78	Analysis of Aurora B Kinase in Non-Hodgkin's Lymphoma Blood, 2008, 112, 1610-1610.	1.4	3
79	CD82 Regulates STAT5/IL-10 and Supports Survival of Acute Myelogenous Leukemia Cells Blood, 2012, 120, 2981-2981.	1.4	3
80	PC-SPES: Molecular mechanism to induce apoptosis and down-regulate expression of PSA in LNCaP human prostate cancer cells. International Journal of Oncology, 2003, 23, 1461-70.	3.3	3
81	Prognostic value of plasma high mobility group box 1 protein and histone H3 levels in patients with disseminated intravascular coagulation: a multicenter prospective cohort study. Thrombosis Journal, 2022, 20, .	2.1	3
82	Digital necrosis associated with chronic cold haemagglutinin disease. British Journal of Haematology, 2016, 174, 343-343.	2.5	2
83	The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a <i>JAK2</i> Exon 12 Mutation. Internal Medicine, 2017, 56, 1705-1710.	0.7	2
84	ZM447439, a Novel Aurora Kinase Inhibitor, Induces Growth Arrest and Apoptosis of Human Leukemia Cells Blood, 2006, 108, 1990-1990.	1.4	2
85	A Case of Acquired von Willebrand Syndrome Complicated by Acute Myelomonocytic Leukemia. Case Reports in Oncology, 2021, 14, 1152-1158.	0.7	1
86	The Anti-Tumor Effects of SU11248, a Class III Receptor Tyrosine Kinase Inhibitor, Against a Variety of Human Hematological Malignancies Blood, 2005, 106, 2795-2795.	1.4	1
87	Beneficial Effect Of Anticoagulants In The Management Of Patients With Acute Promyelocytic Leukemia (APL): Results Of a Multicenter, Retrospective Epidemiologic Study Of The Disseminated Intravascular Coagulation Patients In Japan. Blood, 2013, 122, 2373-2373.	1.4	1
88	A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia. International Journal of Hematology, 2022, , 1.	1.6	1
89	Independent Paroxysmal Nocturnal Hemoglobinuria and Myelodysplastic Syndrome Clones in a Patient With Complete Bone Marrow Failure. HemaSphere, 2018, 2, e142.	2.7	0
90	Weight Loss Intervention before Cord Blood Transplantation in an Obese Patient with Acute Myeloid Leukemia: A Case Study. Progress in Rehabilitation Medicine, 2021, 6, n/a.	0.9	0

#	Article	IF	CITATIONS
91	SOS/TA-TMA. Journal of Illusion, 2021, 10, 136-144.	0.1	Ο
92	Blockade of mTOR Signaling Potentiates the Ability of Histone Deacetylase Inhibitor to Induce Growth Arrest and Differentiation of Acute Myelogenous Leukemia Cells Blood, 2008, 112, 1612-1612.	1.4	0
93	CD34+/CD38- Leukemia Stem Cells Aberrantly Express CD82 Adhesion Molecule. Blood, 2010, 116, 2168-2168.	1.4	0
94	CD34+/CD38â^' Acute Myelogenous Leukemia Cells Aberrantly Express Aurora Kinase A. Blood, 2011, 118, 1886-1886.	1.4	0
95	Recombinant Human Soluble Thrombomodulin Safely and Effectively Rescues Acute Promyelocytic Leukemia Patients From Disseminated Intravascular Coagulation Blood, 2012, 120, 2226-2226.	1.4	0
96	STAT5A Regulates DNMT3 and Inactivates PTEN Tumor Suppressor Gene in CD34+/CD38â^' AML Cells. Blood, 2012, 120, 4087-4087.	1.4	0
97	Effect Of Recombinant Human Soluble Thrombomodulin On Clinical Outcomes Of patients With Coagulopathy After Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 4803-4803.	1.4	0
98	Recombinant Thrombomodurin For The Treatment Of Transplantation-Associated Coagulopathy After Allogeneic Stem Cell Transplantation. Blood, 2013, 122, 5454-5454.	1.4	0
99	HMGA2 Orchestrates the Tumorgenesis of Myeloproliferative Neoplasms (MPN) in Corporation with JAK2V617F. Blood, 2016, 128, 796-796.	1.4	0
100	Autocrine and Paracrine Interactions Between Multiple Myeloma Cells and Bone Marrow Stromal Cells By Growth Arrest-Specific Gene 6 Crosstalk with Interleukin-6. Blood, 2016, 128, 5606-5606.	1.4	0
101	HMGA2 mRNA Expression in Patients with Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN). Blood, 2018, 132, 4384-4384.	1.4	0
102	Introduction of Chromosomal Translocation t(11; 14) and a p53 Deletion into Normal B Cell-Derived iPSCs to Elucidate the Cellular Origin of Myeloma Cells. Blood, 2019, 134, 3057-3057.	1.4	0
103	Knock-Ins of Type-2 Calr Mutants Cause Myeloproliferative Neoplasm (MPN)-like Hematopoiesis in Mice. Blood, 2019, 134, 2964-2964.	1.4	0
104	Diagnosis of Bleeding Tendency and Treatment Based on the Pathological Condition. The Journal of the Japanese Society of Internal Medicine, 2020, 109, 1337-1339.	0.0	0
105	Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial. Blood, 2021, 138, 3601-3601.	1.4	0
106	Normal B Cell-Derived iPSCs Capable of Inducing RAS Mutants and Aid to Explore Myeloma-Initiating Cells. Blood, 2021, 138, 4711-4711.	1.4	0